Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2299 | Maximal effort test Wiki | 0.32 |
| drug2889 | Phone interviews Wiki | 0.32 |
| drug2532 | Neuromuscular evaluation Wiki | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3688 | Sputum analysis Wiki | 0.32 |
| drug4356 | actigraphy Wiki | 0.32 |
| drug1013 | Computed Tomography (CT) Wiki | 0.32 |
| drug593 | Blood analysis Wiki | 0.32 |
| drug4676 | psychological and sociological interviews Wiki | 0.32 |
| drug1837 | Hyperpolarized Xenon-129 MRI of the lungs Wiki | 0.32 |
| drug3639 | Six Minute Walk Test (6MWT) Wiki | 0.32 |
| drug3145 | Pulmonary Function Tests (PFT) Wiki | 0.32 |
| drug4408 | blood test Wiki | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013180 | Sprains and Strains NIH | 0.22 |
| D015673 | Fatigue Syndrome, Chronic NIH | 0.18 |
| D020920 | Dyssomnias NIH | 0.13 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005221 | Fatigue NIH | 0.13 |
| D020447 | Parasomnias NIH | 0.12 |
| D001068 | Feeding and Eating Disorders NIH | 0.11 |
| D009103 | Multiple Sclerosis NIH | 0.07 |
| D012598 | Scoliosi NIH | 0.07 |
| D006973 | Hypertension NIH | 0.06 |
| D007239 | Infection NIH | 0.03 |
| D013577 | Syndrome NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012378 | Fatigue HPO | 0.13 |
| HP:0000822 | Hypertension HPO | 0.06 |
Navigate: Correlations HPO
There are 10 clinical trials
Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This symptom seems particularly pronounced in Covid-19 patients and may affect their quality of life by decreasing their capacity to perform simple tasks of daily life. The aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in the feeling of fatigue of Covid-19 patients. Because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. A better knowledge of chronic fatigue etiology and its recovery will allow to optimize rehabilitation treatments to shorten the persistence of chronic fatigue and in fine improve life quality.
Description: Level of cortical activation and cortico-spinal excitability measured by transcranial magnetic stimulation
Measure: Neuromuscular function : cortical activity Time: 6 weeks post-dischargeDescription: Peripheral function by electrical nerve stimulation
Measure: Neuromuscular function : Peripheral function Time: 6 weeks post-dischargeDescription: measured by effort test
Measure: Maximal oxygen uptake (VO2max) Time: 6 weeks post-dischargeDescription: measured by actigraphy
Measure: quality of sleep Time: 6 weeks post-dischargeDescription: with Magnetic resonance imaging
Measure: muscle volume Time: 6 weeks post-dischargeDescription: measured by a Phosphorus 31 Nuclear magnetic resonance test
Measure: metabolic fatigue Time: 6 weeks post-dischargeThe purpose of this study is to determine whether sleep disturbances in children aged 7 to 12 during COVID-19 containment are more prevalent in children who received routine psychiatric care before containment compared to children who don't have any psychiatric care.
Description: Sleep quality is assessed in both groups with the Sleep Disturbance Scale for Children (SDSC scale). A score ≥ 45/125 is considered as pathological.
Measure: Comparison of sleep quality during COVID-19 containment between children usually followed in child psychiatry and children without follow-up Time: An average of 1 dayDescription: Child depression is measured using Child Depression Inventory Scale (CDI scale). For each item the score is graded by severity from 0 (normal behavior) to 2 (severe).
Measure: Assessment of child depression in both groups Time: An average of 1 dayDescription: Child anxiety is measured using Revised Children's Manifest Anxiety Scale (RCMAS). For each item, child answer by Yes or No. The total score is interpreted using the correspondence tables in function of sex and age
Measure: Assessment of child anxiety in both groups Time: An average of 1 dayDescription: Sleep quality is assessed with the Sleep Disturbance Scale for Children (SDSC scale). The score obtained is interpreted in function of socio-demographic factors (age, sex, lifestyle, couple status, profession and socio-professional category, education)
Measure: Assessment of the influence of socio-demographic factors on sleep in both groups Time: An average of 1 dayDescription: Sleep quality is assessed with the Sleep Disturbance Scale for Children (SDSC scale). For their parents, sleep quality and anxiety level are measured with a numerical scale between 0 and 10. For sleep quality, 0 correspond to a very poor quality and 10 to a very good quality. For anxiety level, 0 correspond to no anxiety and 10 to a severe anxiety. The score obtained for child is interpreted in function of their parents score.
Measure: Measure of the correlation between child sleep quality and parents sleep quality (anxiety level) in both groups Time: An average of 1 dayDescription: Sleep quality is assessed with the Sleep Disturbance Scale for Children (SDSC scale). The score obtained is interpreted in function of child psychiatry diagnoses coded with Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Measure: Assessment of sleep disturbance based on psychiatry diagnoses in the group of children usually followed in child psychiatry Time: An average of 1 dayDescription: Child anxiety is measured using Revised Children's Manifest Anxiety Scale (RCMAS). For each item, child answer by Yes or No. The score obtained is interpreted in function of child psychiatry diagnoses coded with Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Measure: Assessment of child anxiety based on psychiatry diagnoses in the group of children usually followed in child psychiatry Time: An average of 1 dayDescription: Child depression is measured using Child Depression Inventory Scale (CDI scale). For each item the score is graded by severity from 0 (normal behavior) to 2 (severe). The score obtained is interpreted in function of child psychiatry diagnoses coded with Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Measure: Assessment of child depression based on psychiatry diagnoses in the group of children usually followed in child psychiatry Time: An average of 1 dayThis project is based in the implementation of a combined monitoring system (technological solutions and medical visits) in survivors of the critical illness due to the infectious disease by COVID-19. The main objective of the project is to characterize the Post-Intensive Care Syndrome (PICS) and detect early needs for specific treatment.
Description: Health related quality of live scale. Values are directly transformed in T scores (mean=50; SD=10), with higher scores meaning better outcome.
Measure: Change from baseline Short Form 12 Health Survey (SF12) at 12 month Time: Every month during a 12 months follow-up periodDescription: Measure of independent living skills. Values are from 0 to 8, with higher scores meaning better outcome.
Measure: Change from baseline Lawton & Brody Instrumental activities of daily living scale at 12 months Time: Every month during a 12 months follow-up periodDescription: Self-report measure of cognitive dysfunction. Values are from 0 to 22, with lower scores meaning better outcome.
Measure: Change from baseline Perceived Deficits Questionnaire (PDQ) at 12 months Time: Every month during a 12 months follow-up periodDescription: A self-assessment instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient. Values are from 0 to 42, with lower scores meaning better outcome.
Measure: Change from baseline Hospital Anxiety and Depression Scale (HADS) at 12 months Time: Every month during a 12 months follow-up periodDescription: Self-report measure of Post Traumatic Stress Disorder (PTSD) symptoms.
Measure: Change from baseline Davidson Trauma Scale (DTS) at 12 months Time: Every month during a 12 months follow-up period. Values are from 0 to 136, with lower scores meaning better outcome.COVID-19 lockdown presents particular challenges for people living with obesity. Indeed during this period, the lifestyle was deeply modified: diet, activity, and sleep behaviours, home office, take care of child, social distancing... All of these modifications may have led to stress and anxiety. It has been previously demonstrated that high perceived stress levels are correlated with high preference for sweet and fat foods . In this context caution would be exercised in obese patients especially those with binge eating disorders. Indeed binge eating disorder is characterized by compulsive overeating or consuming abnormal amounts of food while feeling unable to stop and a loss of control. And one key trigger of binge eating disorder is stress and anxiety. Thus, patients with binge eating disorders may have been more sensitive to the impact of lockdown and thus urgently would require appropriated care management. The main objective is to compare the eating behaviour between obese patients with or without binge eating disorders. The second objective is to compare the weight evolution between the two groups before and after the lockdown. To reach these objectives, the scientific team of the CIO project proposes to contact by phone and e-mail obese patients (with or without binge eating disorders) who have been hospitalized for their obesity disease before the start of the lockdown in the Endocrinology department of the Lyon Hospital. The patients will be asked to fill in several questionnaires (using an online tool) allowing to evaluate their mood, anxiety, eating behaviour, binge eating disorders… during the lockdown. The results of these questionnaires will be compared to those collected during their hospitalisation before the lockdown. The hypothesis is that participants suffering from binge eating disorder will have more sever eating behaviour perturbations as higher level of stress, anxiety, depressive symptoms.
The intensive care unit occupies a particular place in our health care system. The urgency of the clinical situations, the proportion of deaths encountered, and the daily workload is likely to generate suffering among staff. The health crisis linked to SARS-COV-2 is unprecedented and has leads to the unprecedented mobilisation of care providers, particularly in the ICU. Faced with the massive and growing influx of patients, human, therapeutic and material resources are overwhelmed and the teams are faced with an unusually heavy workload in a context of extreme tension. These professionals are thus exposed to a risk of over-investment, in a context of acute and repetitive stress, over an indeterminate period of time combining workload, emotional intensity with specific ethical issues, simultaneously affecting the professional sphere but also the personal and family sphere (confinement, risk of contamination). Now more than ever, the mental health of caregivers is an important concern, as highlighted by the CCNE. Mental health is understood in the way in which the individual responds specifically to work-related suffering by developing individual and collective defensive strategies. Thus, the issue of mental health in the ICU cannot be considered without taking into account the strategies that professionals put in place to combat stress and to contribute or not to the construction and stabilization of the work collective (collaboration, support). Ethical and/or psychological support systems have been set up in most of the establishments involved in the care of Covid-19 patients. However, the adequacy of these systems relative to the needs of professionals during and after the crisis is not yet known. We hypothesize that the psychological and social repercussions of this pandemic as well as the individual and collective strategies deployed by ICU care providers to deal with it will evolve in view of the progression of the crisis but also of the various types of support, particularly psychological and/or ethical, available to them.
Description: This scale integrates generic stressors as well as factors specific to intensive care and crises.
Measure: PS-ICU Scale Score Time: Through study completion, an average of 6 months after the epidemic peakThe primary goal of this research is to study the prevalence of the wearing-off effect and possible risk factors for wearing-off symptoms in patients with multiple sclerosis using ocrelizumab with the use of questionnaires. Furthermore, the goal is to study whether patients receiving extended dosing of ocrelizumab experience more wearing-off symptoms or adverse events in general. Finally, we would like to extend knowledge on wearing-off symptoms in general.
Description: Prevalence of wearing-off symptoms prior to ocrelizumab infusion (yes/no assessed on questionnaires)
Measure: Wearing-off symptoms Time: BaselineCOVID-19 is associated with acute pulmonary and cardiac injury. To better understand the degree and severity of cardiopulmonary injury as well as short and long-term sequelae of COVID-19 infection, this study will perform longitudinal study in patients who had recent known diagnosis of COVID-19.
Description: Inflammatory markers include D-dimer, ferritin, and CRP measurements
Measure: Level of Inflammatory Markers Time: Up to 12 monthsDescription: Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
Measure: Score on St. George's Shortness of Breath Questionnaire (SGSQ) Time: Up to 12 monthsDescription: Short form ZBI-12 validated as screening tool in advanced illness including dementia and cancer. Total ZBI-12 score: summation of 12 items (0 to 4 points per item, total score range 0 to 48). The higher the score, the higher the burden.
Measure: Score on Short Form Zarit Burden Interview (ZBI-12) Time: Up to 12 monthsCOVID-19 is an emergency situation which broke out from China in 2020. Health commitees and goverment set some rules and limit people's freedom to leave from their houses and it is called as 'social isolation'.Staying at home and disease bring about sedentary lifestyle, anxiety and depression and changed eating habits of all person. Hypertension is an important cardiovasculary risk factor and physical activity, stress managament are very important for disease control. In that study we aimed to assess hypertensive and healthy person's anxiety level, physical activity and qualit of life level during COVID-19 social isolation.
Description: Physical activity level assessed with International Physical Activity Questionnaire (IPAQ) long version. IPAQ long version asks work-related, transport, domestic and recreational physical activities. It categorizes physical activities vigorous, moderate and walking. It uses frequency and duration of activities. Every physical activity category has a point and better physical activity level is related with higher IPAQ scores.
Measure: Physical Activity Time: 2 monthsDescription: It will assess with Short form 36 questionnaire. It assesses quality of life and it contains different parameters for example body function, pain, physical and mental health etc. Each subscale is evaluated between 0-100 points. A higher score indicates the better health.
Measure: Quality of Life Assesment Time: 2 monthsDescription: Healthy lifestyle behavior will asssess with Healthy Life Style Behavior Scale. The reliability and validity of the scale has been studied in Turkey. The lowest score that can be obtained from these three sub-dimensions is 26 and the highest score that can be obtained is 104.Positivite healthy lifestyles related with higher scores.
Measure: Evaluation of Individuals Healthy Lifestyle Behaviors Time: 2 monthsDescription: Hospital Anxiety and Depression Scale (HADS) will use.The HADS contains fourteen item. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains.
Measure: Anxiety and Depression Level Time: 2 monthsThis is a longitudinal study of the long-term impact of COVID-19 on the lungs. Participants will be followed over a period of up to 4 years and impacts of COVID-19 on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129, pulmonary function tests, exercise capacity, computed tomography imaging and questionnaires.
Description: Measured using 129-Xenon MRI ventilation defect percent
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by VDP. Time: 1 yearDescription: Measured using forced expiratory volume in one second (FEV1)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FEV1. Time: 1 yearDescription: Measured using forced vital capacity (FVC)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FVC. Time: 1 yearDescription: Measured using total lung capacity (TLC)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by TLC. Time: 1 yearDescription: Functional residual capacity (FRC)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FRC. Time: 1 yearDescription: Measured using residual volume (RV)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by RV. Time: 1 yearDescription: Measured using forced oscillation technique (FOT)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FOT. Time: 1 yearDescription: Measured using lung clearance index (LCI)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by LCI. Time: 1 yearDescription: Measured using Fractional Exhaled Nitric Oxide (FeNO).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FeNO. Time: 1 yearDescription: Exercise capacity measured by six-minute walk test
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by exercise capacity. Time: 1 yearDescription: Measured using the baseline dyspnea index questionnaire.
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by baseline dyspnea index questionnaire Time: 1 yearDescription: Measured using the modified medical research council (mMRC) dyspnea scale questionnaire.
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by (mMRC) dyspnea scale questionnaire. Time: 1 yearDescription: Measured using the COPD assessment test (CAT).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by CAT. Time: 1 yearDescription: Measured using the St. George's respiratory questionnaire (SGRQ).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by SGRQ. Time: 1 yearDescription: Measured using the International Physical Activity Questionnaire (IPAQ).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by IPAQ. Time: 1 yearDescription: Measured using blood and sputum eosinophil count.
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by eosinophil count. Time: 1 yearDescription: Measured using 129-Xenon MRI ventilation defect percent
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by VDP. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using forced expiratory volume in one second (FEV1).
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FEV1. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using forced vital capacity (FVC)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FVC. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using total lung capacity (TLC)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by TLC. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using functional residual capacity (FRC)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FRC. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using residual volume (RV)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by RV. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using forced oscillation technique (FOT).
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FOT. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using lung clearance index (LCI)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by LCI. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using Fractional Exhaled Nitric Oxide (FeNO)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FeNO. Time: within 3 months post COVID-19 infection recoveryDescription: Exercise capacity measured by six-minute walk test
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by exercise capacity. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the baseline dyspnea index questionnaire.
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the baseline dyspnea index questionnaire. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the modified medical research council (mMRC) dyspnea scale questionnaire
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the mMRC dyspnea scale questionnaire. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the COPD assessment test (CAT)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by CAT. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the St. George's respiratory questionnaire (SGRQ)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by SGRQ. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the International Physical Activity Questionnaire (IPAQ).
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by IPAQ. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using blood and sputum eosinophil count.
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by eosinophil count.. Time: within 3 months post COVID-19 infection recoveryDescription: Evaluated by assessing different genders.
Measure: Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by sex. Time: up to 4 yearsDescription: Evaluated by assessing different age groups.
Measure: Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by age. Time: up to 4 yearsDescription: Evaluated by assessing smoking history measured in pack-years.
Measure: Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by smoking history measured in pack-years. Time: up to 4 yearsThe objective of the study is to identify socio-demographic factors, behaviors and practices associated with infection with SARS-CoV-2 to help determine where and how patients mostly get infected with SARS-CoV-2. It is a case-control study including : - cases identified by the nationwide system of positive SARS-CoV-2 tests (COVID-19 diagnosis information system, SIDEP) (currently limited to qRT-PCR) and invited to participate by the National Health Insurance (CNAM) which hosts the data from the nationwide test system; - controls included via Ipsos, a polling institute with access to personal data from a panel from which they will include controls matched on age (divided into 10-year categories), gender and geographic area (departement); - cases will be offered to invite a person they live with to participate in the study offering another case-control analysis inside a household. These participants will be required to report the result of the test as recommended by contact tracing guidelines to determine whether they are cases or controls. Data will be collected via a self-administered online questionnaire. Some of the participants will be called for a complementary telephone questionnaire to measure reliability of online retrieved data and explore more specific aspects of SARS-CoV-2 transmission.
Description: Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places through case-control analyses.
Measure: Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the online questionnaire Time: 1 yearDescription: Proportion of cases reporting likely contamination circumstances in the family environment
Measure: Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the phone interview Time: 1 yearDescription: Proportion of cases reporting likely contamination circumstances in the family environment
Measure: Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the online questionnaire Time: 1 yearDescription: Proportion of cases reporting likely contamination circumstances in the professional environment
Measure: Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the phone interview Time: 1 yearDescription: Proportion of cases reporting likely contamination circumstances in the professional environment
Measure: Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the online questionnaire Time: 1 yearDescription: Proportion of participants reporting adherence to mask-wearing
Measure: Level of adherence to mask-wearing reported in the phone interview Time: 1 yearDescription: Proportion of participants reporting adherence to mask-wearing
Measure: Level of adherence to mask-wearing reported in the online questionnaire Time: 1 yearDescription: Proportion of participants reporting adherence to hand-washing
Measure: Level of adherence to hand-washing in the phone interview Time: 1 yearDescription: Proportion of participants reporting adherence to hand-washing
Measure: Level of adherence to hand-washing in the online questionnaire Time: 1 yearDescription: Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places through case-control analyses.
Measure: Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the phone interview Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports